pca 4230 has been researched along with cyclin d1 in 1 studies
| Studies (pca 4230) | Trials (pca 4230) | Recent Studies (post-2010) (pca 4230) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 9 | 0 | 0 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrés, V; Font de Mora, J; Goukassian, D; Pérez-Roger, I; Sanz-González, SM; Ureña, J | 1 |
1 other study(ies) available for pca 4230 and cyclin d1
| Article | Year |
|---|---|
Inhibition of the cyclin D1/E2F pathway by PCA-4230, a potent repressor of cellular proliferation.
Topics: Animals; Carrier Proteins; Cell Cycle Proteins; Cell Division; Cells, Cultured; Cyclin A; Cyclin D1; Dihydropyridines; DNA-Binding Proteins; Dose-Response Relationship, Drug; E2F Transcription Factors; E2F1 Transcription Factor; Humans; Luciferases; Muscle, Smooth, Vascular; Promoter Regions, Genetic; Rats; Rats, Inbred F344; Recombinant Fusion Proteins; Retinoblastoma-Binding Protein 1; S Phase; Signal Transduction; Time Factors; Transcription Factor DP1; Transcription Factors; Tumor Cells, Cultured | 2001 |